Thyrocare Technologies reported Q2 FY27 revenue of Rs 270.81 crore, up from Rs 216.53 crore last year. Profit fell to Rs 15.22 crore due to a Rs 44.98 crore impairment loss related to its subsidiary, Nueclear Healthcare. Shareholders are now voting on a Rs 141.40 crore divestment of the subsidiary, a critical move for the company's future balance sheet.
Thyrocare Q2 Results: Revenue Growth Masked by Impairment Charges
Revenue rose to Rs 270.81 crore for the quarter ended September 30, 2026.
Consolidated profit dropped to Rs 15.22 crore compared to Rs 47.81 crore in the year-ago period.
Reader Takeaway: Revenue is growing, but a one-time impairment charge has hit profits; the upcoming subsidiary sale is key.
What just happened
Thyrocare Technologies Limited has released its unaudited financial results for the quarter ended September 30, 2026. While the top-line saw a healthy jump to Rs 270.81 crore, bottom-line profitability was significantly hampered by a one-time exceptional impairment loss of Rs 44.98 crore. This charge is directly tied to the valuation of the company's subsidiary, Nueclear Healthcare Limited (NHL).
Why this matters
The company is in the final stages of divesting its entire shareholding in NHL for an aggregate consideration of approximately Rs 141.40 crore. The deal, which includes a mix of cash and Compulsorily Convertible Preference Shares, is awaiting shareholder approval. The outcome of the voting process, which concludes on October 29, 2026, will determine the company's capital allocation and future asset profile.
Segment Performance
The diagnostics business remains the engine of the company, contributing Rs 256.74 crore in revenue on a standalone basis for the quarter. Meanwhile, the Imaging Services segment reported revenue of Rs 13.55 crore, reflecting the company’s ongoing focus on streamlining its diagnostic-centric core operations.
Risks to watch
Investors should note that the Rs 44.98 crore impairment is an accounting adjustment reflecting the current valuation gap. The main risk remains the successful completion of the NHL sale. Should the divestment hit regulatory or shareholder hurdles, the company may face further re-evaluation of its investment portfolio.
What to track next
The primary monitorable for shareholders is the official outcome of the shareholder vote on the NHL sale scheduled for October 29, 2026. Following the divestment, analysts will be looking at how the cash infusion and shift in strategy impact the company's margins and core diagnostic growth.